Clinical trial • Phase II • Other
sulodexide
Phase II trial of sulodexide. 20 participants.
Overview
- Trial Therapeutic Area
- Other
- Trial Stage
- Phase II
- Drug Modality
- Other
Key dates
- Initial CTIS Submission Date
- 11-07-2024
- First CTIS Authorization Date
- 19-09-2024
Trial design
Phase II trial across 1 site in Portugal.
- Target Sample Size
- 20
Recruitment
- Planned Sample Size
- 20
- Recruitment Window Months
- 2
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 20
Portugal
- Earliest CTIS Part Ii Submission Date
- 04-09-2024
- Latest Decision Or Authorization Date
- 19-09-2024
- Processing Time Days
- 15
- Number Of Sites
- 1
- Number Of Participants
- 20
Sites
- Site Name
- Blueclinical Investigacao E Desenvolvimento Em Saude Lda.
- Department Name
- Medical Management
- Contact Person Name
- Suzana Cecatto
- Contact Person Email
- phase1@blueclinical.pt
- Number Of Participants
- 20
Sponsor
Primary sponsor
- Full Name
- Intexo Societa Benefit S.r.l.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Italy
Investigational products
- Investigational Product Name
- Sulodexide Intexo 250 LRU
- Active Substance
- sulodexide
- Modality
- Other
- Routes Of Administration
- oral (capsule)
- Route
- oral
- Investigational Product Name
- Vessel Due F 250 LRU cps
- Active Substance
- sulodexide
- Modality
- Other
- Routes Of Administration
- oral (capsule)
- Route
- oral
Related trials
Other published trials that may interest you.